손위형제 또는 자매가 있는 소아에서 Palivizumab 투여 여부에 따른 임상적 효과 분석
Analysis of Clinical Effects of Palivizumab for Children with Older Siblings
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background : Palivizumab is an intravenous monoclonal antibody which is used in the prevention of respiratory syncytial virus (RSV) infection. It is currently recommended for infants who are at high-risk for RSV infections due to preterm birth or other medical conditions such as congenital heart disease. Palivizumab is a humanized monoclonal antibody directed against an epitope in the antigenic site A of the protein F of RSV particles. Palivizumab is given once a month via intramuscular (IM) injection throughout the duration of the RSV season. Since palivizumab is known to have preventive effects against RSV infection for children with older siblings, the insurance coverage for palivizumab was expanded in October 2016. Methods : The electronic medical records of children under 2 years old who have older siblings who visited or were admitted to the Severance Hospital from October 2015 to May 2016 and from October 2016 to May 2017 were reviewed retrospectively. The data were then divided into two groups depending on the pilivizumab administration. Results : A total of 67 patients were enrolled in this study. The effectiveness in the reduction of hospitalization was statistically significant (p=0.009). Palivizumab decreased respiratory symptoms such as cough, rhinorrhea, and fever in patients with older siblings (p 0.05). Conclusions : In this study, palivizumab administration was effective in preventing RSV infection in infants with older siblings. Expanding palivizumab-prophylaxis administration to infants with older siblings may be effective in the prevention of upper respiratory infections.
Abstract
Background : Palivizumab is an intravenous monoclonal antibody which is used in the prevention of respiratory syncytial virus (RSV) infection. It is currently recommended for infants who are at high-risk for RSV infections due to preterm birth or other medical conditions such as congenital heart disease. Palivizumab is a humanized monoclonal antibody directed against an epitope in the antigenic site A of the protein F of RSV particles. Palivizumab is given once a month via intramuscular (IM) injection throughout the duration of the RSV season. Since palivizumab is known to have preventive effects against RSV infection for children with older siblings, the insurance coverage for palivizumab was expanded in October 2016. Methods : The electronic medical records of children under 2 years old who have older siblings who visited or were admitted to the Severance Hospital from October 2015 to May 2016 and from October 2016 to May 2017 were reviewed retrospectively. The data were then divided into two groups depending on the pilivizumab administration. Results : A total of 67 patients were enrolled in this study. The effectiveness in the reduction of hospitalization was statistically significant (p=0.009). Palivizumab decreased respiratory symptoms such as cough, rhinorrhea, and fever in patients with older siblings (p 0.05). Conclusions : In this study, palivizumab administration was effective in preventing RSV infection in infants with older siblings. Expanding palivizumab-prophylaxis administration to infants with older siblings may be effective in the prevention of upper respiratory infections.
참고문헌 (18)
- Park HW, "Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age", Pediatr Infect Dis J, 31(8), pp.e99~e104 (2012)
- Lee YI, "Risk factors for acute respiratory syncytial virus infection of lower respiratory tract in hospitalized infants", J Microbiol Immunol Infect, 49(5), pp.737~742 (2016)
- Krisna N.A. Pangesti, "Molecular epidemiology of respiratory syncytial virus", Reviews in Medical Virology, 28(2), pp.e1968~ (2018), Wiley[DOI]
- Thorburn K, "Mortality and morbidity of nosocomial respiratory syncytial virus (RSV) infection in ventilated children-A ten year perspective", Minerva Anestesiol, 78(7), pp.782~789 (2012)
- Rose EB, "Respiratory Syncytial Virus Seasonality - United States, 2014-2017", MMWR Morb Mortal Wkly Rep, 67(2), pp.71~76 (2018)
- Jacoby P, "Characterizing the risk of respiratory syncytial virus in infants with older siblings: a population-based birth cohort study", Epidemiol Infect, 145(2), pp.266~271 (2017)
- "Health insurance review & assurement service: insurance approval standard page" (2016)[URL]
- Mochizuki H, "Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing: 6 Year Follow up Study", Am J Respir Crit Care Med, 196(1), pp.29~38 (2017)
- Kurz H, "Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units", J Hosp Infect, 70(3), pp.246~252 (2008)
- Castillo LM, "One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America", J Pediatr, 93(5), pp.467~474 (2017)
- 장승구, "Outcomes of Palivizumab Prophylaxis for Respiratory Syncytial Virus Infection in Preterm Children with Bronchopulmonary Dysplasia at a Single Hospital in Korea from 2005 to 2009", Journal of Korean Medical Science, 25(2), pp.251~256 (2010), 대한의학회
- Sommer C, "Risk factors for severe respiratory syncytial virus lower respiratory tract infection", Open Microbiol J, 5, pp.144~154 (2011)
- Chan P, "Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab", Pediatr Infect Dis J, 34(12), pp.e290~e297 (2015)
- Mauskopf J, "Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review", Pediatr Infect Dis J, 35(7), pp.e229~e238 (2016)
- American Academy of Pediatrics Committee on Infectious Diseases, "Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection", Pediatrics, 134(2), pp.e620~e638 (2014)
- Alan S, "Outcome of the Respiratory Syncytial Virus related acute lower respiratory tract infection among hospitalized newborns: a prospective multicenter study", J Matern Fetal Neonatal Med, 29(13), pp.2186~2193 (2016)
- Reeves RM, "Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007-2012", Influenza Other Respir Viruses, 11(2), pp.122~129 (2017)
- Hernandez-Gago Y, "Cost effectiveness of a protocol using palivizumab in preterm infants", Farm Hosp, 41(2), pp.169~186 (2017)